- cafead Jun 11, 2020 at 11:02: PM
via Denali Therapeutics and its development partner Sanofi announced data from its Phase Ib trial of DNL747 in Alzheimer’s disease and amyotrophic lateral sclerosis (ALS). After apparent disappointing results, the companies have chosen to pause the studies with the drug and shift their resources to a similar drug, DNL788, for the same indications. Denali shares dropped almost 7% to $23.95 in late market trading after announcing the decision.
article source
article source